Kamagra gibt es auch als Kautabletten, die sich schneller auflösen als normale Pillen. Manche Patienten empfinden das als angenehmer. Wer sich informieren will, findet Hinweise unter kamagra kautabletten.
Use of generic drugs can save both you and your health plan money

 University of Arkansas 
 April 2016 
 Use of generic drugs can save both you and your health plan money. This list is not all-inclusive and is not a guarantee of coverage. Plan Benefit design is the final determinate of coverage. Certain drugs (*) may be subject to Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST), or Reference Based Pricing (RBP) requirements according to Benefit Design. Unless noted, multisource brand drugs (brand drugs with generic equivalent) are covered at 100% copay. If you have any questions about these requirements or other formulary questions, please contact a MedImpact Healthcare customer service representative at 800-788-2949. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics. 
Drug Type 
Antibiotics – Cephalosporins 
cefaclor, cefadroxil, cefdinir, 
CEFTIN susp, SUPRAX 400mg only* (QL) 
(Quantity Limit) 
cefpodoxime, cefprozil, 
Note: all other Suprax strengths are 100% 
cefditoren,cefuroxime, cephalexin 
Antibiotics - Macrolides 
azithromycin, clarithromycin, 
clarithromycin ext-rel, 
erythromycin delayed-rel, 
erythromycin ethylsuccinate, 
erythromycin stearate 
Antibiotics - Fluoroquinolones 
ciprofloxacin, ciprofloxacin ext-rel, 
levofloxacin ,moxifloxacin 
Antibiotics - Penicillins 
clavulanate, dicloxacillin, 
penicillin VK 
Antibiotics – Other* (Prior 
clindamycin HCl, doxycycline 
hyclate, linezolid* (PA), 
minocycline, tetracycline 
Antifungals* (Prior Authorization) 
fluconazole, itraconazole* (QL), 
(Quantity Limit) 
ketoconazole, terbinafine tabs , 
voriconazole 
Antivirals - Influenza* (Quantity 
amantadine, rimantadine 
Antivirals - Herpes 
acyclovir, famciclovir, 
valacyclovir, valganciclovir tab 
Antivirals - Other -
ribasphere, ribavirin 
HARVONI*(PA), PEGASYS* (PA), 
DAKLINZA* (PA), TECHINIVIE* (PA) 
Interferons/Interferon Combinations 
PEGINTRON* (PA), REBETOL 
(Prior Authorization) 
susp, SOVALDI*(PA) 
Anti-Adrenergic Blockers Peripherally 
doxazosin, prazosin, terazosin 
Anticoagulants/Antiplatelet Agents 
cilostazol, clopidogrel, 
AGGRENOX, ELIQUIS (QL), 
( Quantity Limits) 
dipyridamole, ticlopidine, 
PRADAXA (QL), XARELTO (QL) 
Antihyperlipidemics - HMG (Statins) 
RBP: PLAN WILL PAY $0.50/PILL; REMAINING COST WILL BE APPLIED TO 
pravastatin, simvastatin 
REFERENCE BASED PRICING 
ADVICOR, ALTOPREV, CRESTOR, LIVALO, SIMCOR, VYTORIN 
Other Antihyperlipidemic Agents 
cholestyramine, colestipol, 
gemfibrozil 

 University of Arkansas 
 April 2016 
Drug Type 
ACE Inhibitors and ACE Inhibitor 
captopril, captopril-HCTZ, 
enalapril, fosinopril, fosinopril-
hydrochlorothiazide, lisinopril, 
lisinopril-HCTZ, quinapril, 
quinapril HCTZ, ramipril, 
trandolapril 
Angiotensin II Receptor Antagonists* 
candesartan/-HCTZ (ST), 
BENICAR* (ST), BENICAR HCT* (ST), 
(ST), TEVETEN HCT* (ST) 
(ST)/-HCTZ (ST),losartan, 
HCTZ, valsartan/-HCTZ 
Antihypertensive Combinations (Step 
AZOR*(ST), TRIBENZOR*(ST), 
Antihypertensive - Others 
eplerenone 
Beta-blockers* (Quantity Limit) 
atenolol, carvedilol, carvedilol 
BYSTOLIC, COREG CR* (QL), 
ext-rel, metoprolol, metoprolol 
ext-rel, propranolol, propranolol 
Calcium Channel Blockers 
amlodipine, diltiazem ext-rel, 
isradipine, nimodipine, 
nisoldipine, verapamil ext-rel 
Chronic Angina* (Prior Authorization) 
Direct Renin Inhibitors/Combo* (Step 
AMTURNIDE*(ST),TEKTURNA* (ST), 
TEKTURNA HCT* (ST) 
furosemide, 
HCTZ, triamterene-HCTZ, 
torsemide 
Paroxysmal Nocturnal 
Hemoglobinuria Agents* (Prior 
Pulmonary Arterial Hypertension 
sildenafil (PA) 
ADCIRCA* (PA), ADEMPAS* (PA), 
(Prior Authorization) 
LETAIRIS, TRACLEER 
Central Nervous System 
ADHD Medications* (Prior 
DAYTRANA* (ST), VYVANSE* (QL) 
Authorization) (Quantity Limit) (Step 
dexmethylphenidate ext-rel, 
methylphenidate, 
EFFECTIVE 1/1/13 - Extended-
methylphenidate ext-rel, 
Release ADHD medications will not 
modafinil (PA), ADDERALL XR 
be covered for members who are 26 
years and older. Regular release 
ADHD drugs will continued to be 
covered at existing tiers. 
Alzheimer's Disease* 
galantamine,memantine* (age), 
rivastigmine 
Analgesics - Narcotic* (Quantity 
KADIAN (200mg), OXYCONTIN* 
ABSTRAL, FENTORA* (QL), KADIAN 
Limit)(Prior Authorization) 
codeine-APAP, fentanyl 
(40mg,70mg, 130mg, 150mg), 
transdermal/- buccal*(QL), 
hydromorphone, morphine/-ER, 
morphine supp, oxycodone-
/APAP ER, oxycodone 
ibuprofen, propoxyphene, 
propoxyphene napsylate-APAP, 
tramadol/-ER 

 University of Arkansas 
 April 2016 
Drug Type 
Analgesics - Anti-Inflammatory/ 
choline magnesium trisalicylate, 
diclofenac, etodolac, ibuprofen, 
indomethacin ext-rel, 
meloxicam, nabumetone, 
naproxen, naproxen sodium, 
oxaprozin, sulindac 
carbamazepine, clonazepam, 
CELONTIN, GABITRIL 
BANZEL* (PA), DEPAKENE, DEPAKOTE, 
(Prior Authorization) 
clonazepam ODT, diazepam 
(12mg,16mg), STAVZOR 
DEPAKOTE ER, DILANTIN, FYCOMPA, 
(rectal), divalproex 
LYRICA (PA), ONFI (PA), OXTELLAR XR 
gabapentin, lamotrigine, 
oxcarbazepine, phenobarbital, 
phenytoin, primidone, valproic 
acid, zonisamide 
alprazolam/- ext-rel, buspirone, 
diazepam, lorazepam, 
Antidepressants - Other* 
amitriptyline, bupropion/-ext-rel, 
(Quantity Limit) 
clomipramine, desipramine, 
doxepin, mirtazapine, 
nortriptyline, trazodone 
Antidepressants - SSRIs 
citalopram, 
escitalopram ,fluoxetine, 
paroxetine/-ER, sertraline 
Antidepressants - SNRIs 
duloxetine, venlafaxine/-ER 
Antiparkinsonian Agents 
amantadine, benztropine, 
AZILECT, MIRAPEX ER, ZELAPAR 
bromocriptine, cabergoline, 
levodopa ext-rel, entacapone, 
pramipexole, ropinirole/-XL, 
selegiline, tolcapone, 
trihexyphenidyl 
Antimanic Agents 
lithium carbonate 
Antipsychotic Agents* 
aripiprazole* (PA), 
MOBAN, NAVANE 20mg only, 
(Prior Authorization) 
chlorpromazine, clozapine, 
fluphenazine, haloperidol, 
olanzapine, perphenazine, 
paliperidone tabs, quetiapine 
(IR), risperidone, thioridazine, 
Migraine Products* (Quantity Limit) 
almotriptan* (QL), 
CAFERGOT, RELPAX* (ST,QL), ZOMIG 
dihydroergotamine inj, 
ergotamine-caffeine tabs, 
naratriptan (QL), rizatriptan 
(QL), sumatriptan (QL), 
zolmitriptan (QL) 
Multiple Sclerosis Drugs (Prior 
AVONEX, AUBAGIO (PA), BETASERON, 
Authorizatiion)(Quantity Limit) 
GILENYA*(PA)(QL), TECFIDERA (PA) 
Sedative Hypnotics – 
flurazepam, temazepam 
Benzodiazepines (BZD) 
(except 7.5mg and 22.5mg), 
triazolam 
Sedative Hypnotics* - Non-
zaleplon* (QL), zolpidem* (QL) 
RBP: PLAN WILL PAY $0.19/PILL; REMAINING COST WILL BE APPLIED TO 
Benzodiazepine (Quantity Limit) 
REFERENCE BASED PRICING 
zolpidem tartrate ER* (QL,RBP), EDLUAR*(QL,RBP),eszopiclone 
(QL,RBP)INTERMEZZO*(RBP),ROZEREM* (QL,RBP), SILENOR*(QL,RBP), 

 University of Arkansas 
 April 2016 
Drug Type 
Skeletal Muscle Relaxants 
baclofen, carisoprodol, 
RBP: PLAN WILL PAY $0.09/PILL; REMAINING COST WILL BE APPLIED TO 
REFERENCE BASED PRICING 
chlorzoxazone, 
cyclobenzaprine, 
methocarbamol, tizanidine 
orphenadrine (RBP), orphenadrine compound (RBP), metaxalone (RBP), 
Other Dermatologicals*(Prior 
fluorouracil, spinosad*(PA) 
Rectal Preparations 
lidocaine HC 
ANAMANTLE HC (0.5 %-3 %) 
Endocrine 
Diabetes - Insulin 
HUMALOG, HUMALOG MIX, 
HUMULIN, LANTUS/-SOLOSTAR, 
NOVOLIN, NOVOLOG 
Diabetes - Insulin Sensitizing 
metformin/-XR, pioglitazone 
Agents*(Prior Authorization) 
Diabetes - Insulin Secreting Agents 
chlorpropamide, glimepiride, 
glipizide, glipizide ext-rel, 
glyburide, tolazamide 
Diabetes - Combinations 
AVANDIA* (PA), AVANDAMET* (PA), 
metformin, metformin ext-rel, 
AVANDARYL* (PA), JANUVIA, 
Diabetes - Other Medications 
GLYSET, GLUCAGON 
BYETTA*(ST), SYMLIN 
EMERGENCY KIT* (QL) 
Diabetic - Supplies 
$0 copay for ABBOTT and BAYER Test Strips, Lancets, Alcohol 
Swabs, Insulin Needles, and Syringes. 
GLUCOMETER**, HUMAPEN MEMOIR, 
LIFESCAN TEST STRIPS, ROCHE TEST 
STRIP and all other NON-ABBOTT/NON-
BAYER Test strips 
levothyroxine 
Antispasmodic/GI Motility 
phenobarbital, 
atropine, glycopyrrolate, 
hyoscyamine/-ext rel, 
lactulose, peg 3350-
GOLYTELY, MOVIEPREP, SUPREP 
electrolytes, polyethylene 
pancrelipase 
CREON, PANCREAZE, ULTRESA, 
ZENPEP (EXCEPT ZENPEP 5K-17K-27K 
Gallstone Solubilizing Agents 
cimetidine, famotidine, 
nizatidine, ranitidine 

 University of Arkansas 
 April 2016 
Drug Type 
Genitourinary Medications 
bethanechol, oxybutynin 
RBP: PLAN WILL PAY $0.30/PILL; REMAINING COST WILL BE APPLIED TO 
REFERENCE BASED PRICING 
chloride, phenazopyridine, 
potassium citrate 
oxybutynin ext-rel (2nd Tier 
tolterodine/-XL (RBP), trospium (RBP), GELNIQUE (RBP), MYRBETRIQ (RBP), 
OXYTROL (RPB), TOVIAZ (RBP), VESICARE (RBP) 
Inflammatory Bowel* (Quantity Limit) 
balsalazide, budesonide, 
APRISO*(QL), DELZICOL*(QL), 
CANASA, DIPENTUM, ENTOCORT EC, 
mesalamine, sulfasalazine, 
GIAZO, UCERIS* (ST) 
sulfasalazine delayed-rel 
Immunosuppressive Agents 
Immunosuppressive* (Prior 
azathioprine, cyclosporine, 
AZASAN, RAPAMUNE, ZORTRESS*(PA) 
cyclosporine modified, 
(caps/tabs), tacrolimus caps 
Men's Health 
Erectile Dysfunction* (Prior 
MUSE* (PA) (QL), VIAGRA* (PA) 
CIALIS* (PA) (QL), LEVITRA* (PA) (QL), 
Authorization) (Quantity Limit) 
STENDRA*(PA), STAXYN* (PA) 
Hormone Replacement * 
testosterone cyprionate, 
(Prior Authorization) 
testosterone enanthate 
EFFECTIVE ON 1/1/15 – TOPICAL TESTOSTERONES ARE COVERED AT 
alfluzosin, dutasteride, 
finasteride, tamsulosin 
Ophthalmics 
Anti-Allergic Agents 
azelastine,cromolyn, epinastine 
ALAMAST, ALOCRIL, ALOMIDE, 
EMADINE, LASTACAFT, PATADAY 
Anti-Infective/Antiviral Agents 
bacitracin, ciprofloxacin, 
AZASITE, VIGAMOX 
erythromycin, gentamicin, 
gramicidin, ofloxacin, 
levofloxacin, polymyxin B-
bacitracin, polymyxin B-
trimethoprim, sulfacetamide, 
tobramycin, trifluridine 
Anti-Glaucoma Agents/ Beta-
betaxolol, brimonidine, 
ALPHAGAN P (0.10%), BETIMOL, 
blockers (Quantity Limit) 
dipivefrin, latanoprost, 
BETOPTIC S, COMBIGAN, COSOPT 
levobunolol, metipranolol, 
PF,LUMIGAN (0.01%), RESCULA 
pilocarpine, timolol, Carboptic 
Anti-Inflammatory Agents 
bromfenac, dexamethasone, 
FLAREX, FML FORTE, FML 
ACUVAIL, ALREX, LOTEMAX 
diclofenac sodium, 
S.O.P., MAXIDEX, NEVANAC, 
fluorometholone, 
prednisolone acetate, 
prednisolone phosphate 
Respiratory 
Nasal Products* (Quantity Limit) 
azelastine*(QL), flunisolide, 
RBP: PLAN WILL PAY $22.42/inhaler; REMAINING COST WILL BE APPLIED 
REFERENCE BASED PRICING 
fluticasone* (QL) 
budesonide spray/pump (QL,RBP), triamcinolone* (QL,RBP), BECONASE 
AQ* (QL,RBP), DYMISTA (RBP), NASONEX* (QL,RBP), OMNARIS* (QL,RBP), 
QNASL* (RBP), VERAMYST* (QL,RBP), ZETONNA (RBP) 

 University of Arkansas 
 April 2016 
Drug Type 
Tier 1 
Asthma -Leukotriene Modulators* 
montelukast, zafirlukast* (ST) 
Asthma - Steroid Inhalants 
budesonide neb soln 
FLOVENT DISKUS/-HFA QVAR 
AEROBID, AEROBID-M, ALVESCO, 
ASMANEX, AZMACORT, DULERA 
Asthma - Beta Agonists Short Acting 
Albuterol/-ER albuterol 
PROAIR HFA, PROVENTIL HFA 
inhalation soln, metaproterenol, 
terbutaline 
Asthma - Beta Agonists - Long Acting 
FORADIL, SEREVENT 
BROVANA, PERFOROMIST 
Asthma - Other* (Prior Autorization) 
ipratropium soln, theophylline 
ADVAIR DISKUS, ADVAIR HFA, 
BREO ELLIPTA, DALIRESP* (PA), 
anhydrous 
ANORO ELLIPTA, ATROVENT 
STRIVERDI RESPIMAT, 
HFA, COMBIVENT, SPIRIVA/- 
SYMBICORT,TUDORZA, XOLAIR* (PA) 
acetic acid, acetic acid-
COLY-MYCIN S, CORTISPORIN-
aluminum acetate, acetic acid-
hydrocortisone, ciprofloxacin, 
polymyxin B-hydrocortisone, 
ofloxacin otic 
ciclopirox soln 
betamethasone dipropionate 
ELIDEL, CORTISPORIN 
 CORDRAN, FINACEA (15%) gel , 
0.05% gel/oint/cream/lotion, 
fluocinolone scalp oil, triamcinolone spray, 
betamethasone valerate 0.1% 
lot/cream/oint, calcipotriene 
soln, clobetasol 0.05% 
betamethasone, fluocinolone, 
lidocaine, mometasone furoate, 
triamcinolone 0.1%, 0.25% 
cream/oint/lotion or 0.5% 
cream/oint 
Skin – Acne* (Prior Authorization) 
adapalene, benzoyl peroxide, 
ALA-QUIN, AZELEX 
clindamycin, metronidazole, sulfacetamide-sulfur, isotretinoin*(PA), tretinoin 
Women's Health 
Antineoplastic - Hormonal Agents 
tamoxifen 
Contraceptives* (All Contraceptives 
$0 copay for contraceptives 
subject to Quantity Limit) 
nclude: generic oral 
contraceptives such as ethinyl 
medroxyprogesterone acetate, 
Apri, Kariva, Levora, Low-
Ogestrel, Necon Sprintec, 
Trinessa, 
ORTHO-EVRA patch, 
CLIMARA PRO, COMBIPATCH, 
PREFEST, PREMPHASE, 
PREMPRO, PREMPRO LOW 
Hormone Replacement Therapy 
estradiol,estradiol patches 
ALORA, CENESTIN, MENEST, 
CLIMARA PRO, DIVIGEL, ELESTRIN, 
MENOSTAR, MINIVELLE, 
ENJUVIA, ESTRACE vaginal cream, 
micronized*(PA) 
ESTRING, FEMRING, FEMTRACE 
NOTE: If a product may be used to 
treat infertility prior authorization will 
be required. 

 University of Arkansas 
 April 2016 
Drug Type 
Tier 1 
alendronate 
RBP: PLAN WILL PAY $0.26/PILL; REMAINING COST WILL BE APPLIED TO 
REFERENCE BASED PRICING 
ACTONEL (RBP), ATELVIA (RBP), ibandronate 150mg (RBP) 
etidronate, 
Prenatal Vitamins 
Vaginal Products* (Quantity Limit) 
clindamycin, clotrimazole, 
fluconazole* (QL on 150mg), 
metronidazole, terconazole 
Antiemetics* (Quantity Limit) 
granisetron* (QL), ondansetron* 
EMEND caps* (QL) 
ANZEMET* (QL), CESAMET* (PA), 
(QL), trimethobenzamide caps 
Antineoplastic Enzyme Inhibitors* 
NEXAVAR* (PA), SPRYCEL* (PA), 
(Prior Authorization) 
Antineoplastic Immunomodulator 
Agents* (Prior Authorization) 
Growth Hormone (Prior 
GENOTROPIN* (PA), 
HUMATROPE* (PA), OMNITROPE* (PA), 
NORDITROPIN* (PA), 
SAIZEN* (PA), SEROSTIM* (PA), TEV-
NUTROPIN* (PA), NUTROPIN 
Hematopoietic Growth Factors 
ARANESP * (PA), EPOGEN* (PA), 
Insulin-Like Growth Factors* (Prior 
cevimeline 
CUVPOSA,NASCOBAL, NARCAN 
Neurological Disease, misc (Prior 
Rheumatoid Arthritis (Prior 
methotrexate 
HUMIRA* (PA), TREXALL 
ACTEMRA SC* (PA), ENBREL* (PA), 
ORENCIA* (PA), REMICADE* (PA), 
Smoking Cessation 
bupropion ext-rel, nicotine 
CHANTIX, NICOTROL INHALER 
transdermal 
 
FOR YOUR INFORMATION: Generics should be considered the first line of prescribing. This drug list represents a 
summary of prescription coverage. It is not inclusive and does not guarantee coverage. Specific prescription benefit plan 
design may not cover certain categories, regardless of their appearance in this document. The plan participant's 
prescription benefit plan may have a different copay for specific products on the list. Unless specifically indicated, drug list 
products will include all dosage forms. This list represents brand products in CAPS, branded generics in upper- and 
lowercase Italics, and generic products in lowercase italics. Generics listed in therapeutic categories are for 
representational purposes only. This is not an all-inclusive list. Listed products may be available generically in certain 
strengths or dosage forms. Dosage forms on this list will be consistent with the category and use where listed. Log in to 
www.medimpact.com to check coverage and copay information for a specific medicine. 
1 Copayment, copay or coinsurance means the amount a plan participant is required to pay for a prescription in 
accordance with a Plan, which may be a deductible, a percentage of the prescription price, a fixed amount or other 
charge, with the balance, if any, paid by a Plan. 
2 Atacand should be reserved for plan participants who meet CHARM (Candesartan in Heart Failure – Assessment of 
Reduction in Mortality and Morbidity) trial criteria. 

 University of Arkansas 
 April 2016 
 This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. 
Prescription Drug Benefits Under the University of 
Arkansas Prescription Drug Program 
Summary of Benefits 
Effective January 2016 
MedImpact Healthcare Systems, Inc. is the prescription benefit manager of this plan. 
 
Retail Day's Supply Limitations: 
Up to 90-day supply (one retail copay applies for each 30-day supply purchased). 
Mail Service Days' Supply Limitations: 
Up to 90-day supply on maintenance medicines (members must fill a 60-day supply within a one year period in order to use mail service, one retail copay applies for each 30-day supply purchased). 
Standard Copay Amounts: 
Retail (up to 30-day supply) 
Mail Service (up to 90-day supply) 
 Note: High cost generics may have non-tier 1 copays. 
Out of Pocket Maximum 
Individual 
Pharmacy Benefit Manager 
MedImpact Healthcare Systems, Inc. Customer Service: 800-788-2949 
Mail Service Pharmacy: 
MedVantx Pharmacy Services Tel: 866-744-0621 Fax: 605-978-3999 
Formulary Type: 
3-Tier Primary/Preferred Drug List 
Dependent Age Limitations: 
Children may be covered until the end of the month in which they turn age 26. 
Prescription Benefit Drug Card Produced 
To order a new a new ID card, call UMR at 1-888-438-6105. 
Refill Restrictions: 
Plan participant must use 50 percent of medicine before refill permitted at retail (60 percent if refilled through mail service or Choice90). 
Paper Claim Reimbursement for Plan 
If plan participant fails to use prescription drug card at a retail pharmacy and submits a 
paper claim to MedImpact Healthcare Systems for reimbursement, the claim will be paid at the same rate the pharmacy would have been paid, less the applicable copay. There is also a $3.00 processing fee withheld from plan participant reimbursement. Paper claim forms available online 
Pharmacy Network: 
Full pharmacy network; most pharmacies in Arkansas are included. For a complete list of participating pharmacies, please log in as a membe 
Compounded Drug Reimbursement 
It is the policy of the University of Arkansas to place all compounded drugs at third tier 
($80 copay) under the prescription drug program. A compounded drug is considered to be any drug that is combined with another drug outside of the manufacturer's setting. This policy includes the compounding of one or more generic drugs. 
Brand Drug Status When Generic is 
If the brand drug has a generic equivalent, the member will be responsible for 100% of the 
Available: 
brand drug cost. 
Brand Drugs with Generic Copay 
Due to manufacture pricing, Adderall XR brand name will be available for a generic copay. The generic version will not be covered by the University of Arkansas (subject to change). 
Generic Drugs with Brand Copay 
Some high cost generics may have non-tier 1 copays. Please consult your PDL for more information or call MedImpact Healthcare Systems, Inc. at 800-788-2949. 
Blood Glucose Monitors 
One per calendar year. Bayer and Abbott brands preferred. All other manufacturers will return a non-formulary copay. 
Compounded Medications 
Covered up to $200 per fill. All compound medications are third tier. 
Dose Optimization 
For drugs where FDA approval is once-daily dosing and different strengths are available at similar costs, quantity limits are set at 1 pill per day for the lower strengths in order to decrease costs and increase compliance. For example, if a member is taking two 20mg strength per day and the drug is available in a 40mg strength, a switch to the higher unit dose may be required. The dose optimization program includes but is not limited to, the following drugs (brand and generics): Coreg CR, Cymbalta, Effexor XR, Mirapex ER, Toprol XL, Ultram ER and Vyvanse. 
The University of Arkansas Pharmacy Advisory Committee, comprised of physicians, pharmacists and benefit specialists, makes all formulary, quantity and days' supply limitations decisions after careful consideration based upon published evidence-based medical data. 
Please note that the University of Arkansas Preferred Drug List (PDL), administered by MedImpact Healthcare Systems, is 
not intended to be inclusive or exclusive of all drugs on the market, but reflects the more commonly used drugs. Be sure to 
verify coverage per plan programs and limitations. You may call MedImpact Customer Service toll-free at 1-800-788-2949 or 
log in as a member at
 
 (QL) = Quantity or Age Limits (ST) = Step Therapy 
*NOTE: Only Bayer and Abbott testing supplies (test strips, lancets) are $0 when purchased with a doctor's prescription. All other brands 
are considered tier 3, $80 copay. 
** Receive a No Cost Blood Glucose Monitoring System 
Blood glucose monitoring systems from Abbott and/or Bayer Healthcare are available by calling Abbot at (866) 224-8892 or Bayer at 
(888) 832-1039 (code BDC-MI). These are the preferred manufacturers for diabetic testing supplies for the University of Arkansas 
and are available at zero copayment. All other brands are considered tier 3, $80 copay. 
PRIOR AUTHORIZATION REQUIRED (PA): 
 
A process that evaluates the drug's prescribed use against a predetermined set of criteria to determine whether your employer will cover 
the medication. In most cases, if the physician does not submit a prior authorization prior to you presenting your prescription at the 
pharmacy, the claim will be denied at point of service. Contact MedImpact Customer Service toll-free at 1-800-788-2949 with questions and 
to begin the prior authorization process. 
To obtain a list of drugs that requires a Prior Authorization please consult your PDL or Medimpact's member website. 
 
IMPORTANT INFORMATION ON THE PRIOR AUTHORIZATION PROCESS: 
MedImpact Healthcare Systems will provide the necessary paperwork to the prescriber for medications that require prior authorization. 
Plan participant or prescriber must contact MedImpact Customer Service toll-free at 1-800-788-2949 to begin the prior authorization 
process. In the event a request for prior authorization is denied, plan participants are to contact MedImpact Healthcare Systems toll-
free at 1-800-788-2949 if they wish to make an appeal. All appeals information can be sent to MedImpact Healthcare Systems, P.O. Box 
509098, San Diego, CA 92150-9098 or fax to: 858-790-6060. 
QUANTITY LIMITS (QL): 
A quantity limitation refers to the maximum days' supply or quantity of a medication that you can obtain at one time under your 
prescription benefits (example up to a 30 day supply or 100 unit dose). Sometimes general therapeutic categories, specific drug classes or 
individual medications may have additional quantity limitation restrictions. Please consult your PDL or MedImpact's member website to 
see if your drug has a quantity limit associated with it. 
 
EXCLUSIONS: 
Most drugs that are excluded under the University of Arkansas will be allowed to process but the member will be responsible for 100% of 
the drug cost. 
Drugs may be added to the exclusion list at any time. Please be sure to verify coverage per plan programs and limitations. You may call 
MedImpact Customer Service toll-free at 1-800-788-2949 or log in as a member at https://mp.medimpact.com/uas. The majority of 
exclusions will be allowed to process, however the member will be responsible for 100% of the cost of the medication. The University of 
Arkansas System will not share in the cost. 
Note: FDA approval of a drug does not guarantee inclusion as a covered item under the Prescription Drug program. Newly approved drugs 
are subject to review by the Pharmacy Advisory Committee before being covered or may be excluded altogether. In addition, the level of 
coverage for some Prescriptions may vary depending on the medication's therapeutic classification. As a result, some medications 
(including, but not limited to, newly approved Prescriptions) may be subject to quantity limits or may require prior authorization before 
being dispensed. 
REFERENCE BASED PRICING (RBP): 
 
Drugs to Treat Insomnia 
Generic and Branded insomnia drugs will be covered up to $0.19 per pill. Any additional cost will be applied to the copay. (Examples include: Ambien, Ambien CR, Edluar, Lunesta, Rozerem, Sonata). Zolpidem (generic Ambien) will continue to be available at the standard copay rates. 
Overactive Bladder Drugs 
Generic and Branded overactive bladder drugs will be covered up to $0.30 per pill. Any additional cost will be applied to the copay. (Examples include: Detrol, Detrol LA, Ditropan XL, Enablex, Sanctura, Vesicare, and Oxytrol Patches). Oxybutynin Immediat release (generic Ditropan) will continue to be available at the standard copay rates, and Oxybutynin Extended Release (generic Ditropan XL) will be available at a tier 2 copay. 
Skeletal Muscle Relaxants 
Generic and Branded skeletal muscle relaxants (oral formulations) will be covered up to $0.09 per pill. Any additional cost will be applied to the copay. (Examples include: Amrix, Fexmid, Norflex, Skelaxin, Soma, and Zanaflex). Baclofen, carisoprodol, cyclobenzaprine, methocarbamol, tizandine,and chlorzoxazone will continue to be available at the standard copay rates. 
Nasal Steroids 
Generic and Branded nasal steroids will be covered up to $22.42 per device. Any additional cost will be applied to the copay. (Examples include: Beconase AQ, Flonase, Nasacort AQ, Nasalide, Nasarel, Nasonex, Omnaris, Rhinocort AQ, and Veramyst). Fluticasone (generic Flonase) and flunisolide (generic Nasalide) will continue to be available at the standard copay rates. 
Osteoporosis Drugs 
Generic and Branded osteoporosis drugs will be covered up to $0.26 per pill. Any additional cost will be applied to the copay. (Examples include: Actonel, Actone w/ Calcium, Atelvia, Boniva, Fosamax, and Fosamax-D). Alendronate (generic Fosamax) will continue to be available at the standard copay rates. 
‘Statin' Drugs to Treat Cholesterol 
Branded statin drugs and statin combos will be covered up to $0.50 per pill. Any additional costs will be applied to the copay. (Examples include: Advicor, Alotprev, Crestor, Lescol/-XL, Lipitor, Livalo, Simcor, Vytorin). Generic atorvastatin, lovastatin, pravastatin and simvastatin will continue to be available at the standard copay rates. 
 
DRUGS TO TREAT ADHD: 
Extended Release (ER) ADHD Drugs 
Extended release formulations (Examples include: Adderall XR, Concerta, Vyvanse) of drugs used to treat ADHD are covered for individuals 25 years of age and younger. Non-ER ADHD medications are available at the applicable benefit with no age restrictions. 
Source: https://hr.uark.edu/documents/prescription-formulary.pdf
   The Intolerance Testing Group TITLE FIRST NAME LAST NAME POST/ZIP CODE COUNTY Please find attached your intolerance test results. You will find two headings within this report, the first section which lists all the food intolerances and the second section which lists all the non-food intolerances. Some of the items will have a further explanation next to them to further detail the intolerances. Everything on here has an intolerance level of over 85% as you will see from the percentage levels on the right hand side. This means they are all high intolerances. We only report these as they are the ones likely to be causing you the most symptoms. However, your hair sample has been tested against all 600 items in our system and this is why there may be items on there you don't recognise or haven't eaten. This is because you have been tested against them regardless. 
    The Role and Use of PEA in Depression & Neurobehavioral Disorders  by DR RICHARD CLARK KAUFMAN   The Phenylethylamine Hypothesis of Depression According to the "Phenylethylamine Hypothesis of Depression" proposed in 1974, the endogenous trace amine Beta- Phenylethylamine (PEA) sustains psychological energy just as thyroid hormone sustains physical energy And a deficit of PEA produces depressions. The Phenylethylamine hypothesis goes on to state that PEA is a neuromodulator of mood, attention, pleasure-seeking behavior, and libido. The phenylethylamine hypothesis led to simple safe and effective way of treating depression and other affective disorders by based on years of research conducted by Dr. Hector Sabelli and colleagues. Take an oral replacement of PEA as replacement to correct an underlying deficiency or defect in neural transmitter functioning. The majorities of depressed individuals show a significant reduction in their symptoms or have complete recovery without any adverse reactions. Plus, there're is significant increases in cognitive performance functions, attention, awareness, and feelings of pleasure, libido, normal social behavior and sense of wellbeing.  PEA. More than Endogenous Amphetamine in our Brain  The Phenylethylamine Hypothesis of Depression stems from the observation that amphetamines increased energy and relieved depressive symptoms of depressive patients. Amphetamine is essentially phenylethylamine with an added methyl group. Studies show that PEA induces behavioral and electrophysiological effects similar to those of amphetamine. Unlike amphetamine, PEA is endogenous to the brain and does not develop tolerance or dependency, or produce any side effects. The stimulant effects of amphetamines and PEA are attributed to the release of catecholamines (noradrenalin, dopamine). This is the basis for the catecholamine hypothesis of depression. However current research shows that PEA is significantly more effective than amphetamine in relieving depression and has therapeutic value in a wide range of neurological and behavioral disorders, Endogenous Mesencephalic Enhancer and Transmitter Signal Amplifier Starting around 1995, Dr Joesph Knoll and his colleagues began presenting their evidence of PEA as an endogenous "mesencephalic enhancer". There are enhancer-sensitive neurons in the brain work in a split-second on a high activity level due to endogenous enhancer substances. The mesencephalic enhancer PEA enhancers of the impulse propagation mediated release of catecholamines (dopamine, epinephrine) and serotonin in the brain.